Background: Olfactory neuroblastoma is a rare malignancy of the nasal cavity.
Introduction
Malignancies of the nasal cavity are uncommon and comprise less than 1% of all malignancies [1] . While almost half of the sinonasal cancers are squamous cell carcinomas [2] , olfactory neuroblastoma, also known as esthesioneuroblastoma, comprise less than 6% of nasal malignancies [3] [4] [5] [6] . After the initial description in 1924 by Berger and Luc, less than 1,000 cases were reported until 1997 [7] . These are tumours of neuroectodermal origin which are thought to arise from the olfactory epithelium in the nasal cavity [8] . The mean age at presentation is 53 years, with most cases occurring in patients between 40 and 70 years of age. Although there is a male predominance [9] , no other risk factor is commonly associated with this disease. The most widely used staging system is the Kadish clinical staging system based upon the extent of the primary tumour [10] . Kadish stage A tumours are confined to the nasal cavity, stage B tumours have involvement of one or more paranasal sinuses, and stage C tumours extend beyond the nasal cavity and paranasal sinuses. This was subsequently modified to include another group of patients with lymph node or distant metastases as stage D tumours [11] . A retrospective analysis of 261 patients with modified Kadish staging showed 10 year disease-specific survival rates of 90%, 68%, 67% and 36% for patients with stage A, B, C, and D respectively [9] . Furthermore, tumour grade may also be a prognostic factor with Morita et al. [11] showing that five-year survival rate was 80% for the low-grade tumours and 40% for the high-grade tumours (P = 0.0001).
The treatment of olfactory neuroblastoma routinely incorporates surgery and post-operative radiotherapy to 55-65 Gy [12] [13] [14] [15] [16] [17] . Multiple studies have incorporated various chemotherapy regimens in an effort to improve outcomes [18] [19] [20] , although there is no randomised data to definitively show that this improves outcomes. Nevertheless, some promising results have been shown in studies of patients with advanced or high grade tumours by Eich et al. [19] . They described a study of 47 patients with more advanced local disease (Kadish stage B and C) who were treated with surgery alone (seven patients), surgery with post-operative radiotherapy (15 patients), definitive radiotherapy with or without chemotherapy (12 patients) and trimodality therapy (with 13 patients received surgery plus chemotherapy plus postoperative radiotherapy). The 5 year overall survival (OS) for the whole group
Here we report on a case of radiotherapy-related olfactory neuroblastoma who was safely re-treated with sequential (dose-reduced) radiotherapy and chemotherapy with an excellent outcome.
A 48 year old male presented with a two month history of occasional headaches, left nostril epistaxis, blocked nose and loss of sense of smell in December 2000. His past medical history included hyperthyroidism and Graves' ophthalmopathy, for which he was treated with anti-thyroid medications and 20 Gy of radiotherapy to his retro-orbital area in 1992. MRI at the time of presentation ( Figure 1 ) revealed a heterogeneous mass lesion in the left nasal cavity with involvement of the medial wall of the left orbit, multiple paranasal sinuses (left ethmoid, bilateral maxillary sinuses and left sphenoid sinuses) and bilateral frontal lobe invasion. The patient underwent an endoscopic biopsy which reported the presence of olfactory neuroblastoma. He underwent left lateral rhinotomy, medial ethmoidectomy, maxillectomy, sphenoidectomy, and a frontal craniotomy with macroscopic clearance of intracranial disease. Histology confirmed the diagnosis of olfactory neuroblastoma and the tumour was considered high grade ( 
patients (74% vs 41%; p = 0.05). The 11 patients with Kadish stage C tumours appeared to derive the most benefit with trimodality therapy (5-year EFS of 72% vs 17%; p = 0.01). This group of patients also tended to have an improved OS (69% vs 47; p = 0.19) compared with the other treatment groups. Interestingly, none of the patients with multimodality treatment had a metastatic relapse [19] . The patient was offered both post-operative radiotherapy and chemotherapy as he was felt to be high risk from the presence of several poor prognostic factors (higher stage, high grade and positive margin). It was considered feasible to deliver 48 Gy to the areas of risk, with the dose being constrained by his previous 20 Gy of radiation to the retro-orbital area for management of Graves' ophthalmopathy in 1992. As a result of the reduced dose of radiotherapy, this was followed by six cycles of chemotherapy consisting of cisplatin 100 mg/m 2 in three divided doses and etoposide 240 mg/m 2 in two divided doses. He tolerated chemotherapy well with some minor delays due to neutropenia. The patient has been followed up for 12 years now with regular clinical and MRI surveillance. He remains in remission with no evidence of tumour recurrence. The only long term toxicities reported were left sided cataract and a blocked left lacrimal duct. He has not developed optic nerve or chiasmal damage.
Discussion
We described an interesting case of a man who presented with an olfactory neuroblastoma that was diagnosed within the irradiation field 8 years after the original radiotherapy for the management of Grave's ophthalmopathy. The tumour could reasonably be ascribed to the prior radiotherapy given that it fits the accepted criteria for radiation-induced tumours, namely that the second tumour (olfactory neuroblastoma) is histologically distinct from the condition that radiotherapy was initially given for (Grave's disease), the tumour was within the prior radiation field and it developed more than 5 years after the radiotherapy [21] . After multi-disciplinary assessment, it was decided to proceed with trimodality treatment (maximal surgical resection, with postoperative chemo-radiotherapy). Despite his previous radiotherapy, post-operative radiotherapy dose was well tolerated and the only late radiation toxicity described was cataracts, which manifested three years after re-irradiation, and anosmia. Chemotherapy was also adequately tolerated. The patient continues on surveillance as late recurrent are possible even up to 15 years from the time of diagnosis [17] .
There have been only four other case reports of radiation induced olfactory neuroblastoma in the literature [22] [23] [24] [25] . Two cases occurred after prior radiotherapy and chemotherapy and outcomes were poor. Kounami et al. reported in 2001 a 17 year old woman diagnosed with olfactory neuroblastoma nine years after the successful treatment of childhood acute leukaemia including 24 Gy prophylactic cranial irradiation, 12 Gy total body irradiation and autologous bone marrow transplantation. Her olfactory neuroblastoma responded briefly to treatment with chemotherapy but she died 11 month later of recurrent disease [24] . McVey et al. reported in 2009 a 61 year old woman who developed metastatic olfactory neuroblastoma 25 years after receiving 60 Gy radiotherapy to the left facial and neck area and MBACOD chemotherapy (methotrexate with leucovorin, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) for the treatment of diffuse large cell poorly differentiated lymphocytic lymphoma. The patient was treated with a palliative course of carboplatin-etoposide but did not respond to treatment [22] . The remaining two cases occurred after prior radiotherapy alone. Perez et al. reported in 2011 a 52 year old female who developed Kadish stage C olfactory neuroblastoma 9 years after 58 Gy whole brain radiotherapy with frontal boost for grade two astrocytoma. The patient was treated with combination of 50 Gy radiotherapy and chemotherapy consistent of docetaxel, cisplatin, and fluorouracil. However, she relapsed in one year and she died shortly after [23] . Lastly, Park et al. reported in 2008 a 59-year-old woman who was diagnosed 20 years after receiving 54 Gy of post-operative radiotherapy for a pituitary adenoma. She was treated with ifosfamide, cisplatin, and etoposide and remained disease free after 4 years of follow up [25] .
Conclusion
We describe a case of likely radiation-induced olfactory neuroblastoma, adding to the increasingly strong case that prior radiotherapy is a risk factor for these rare tumours. Within the limits of the sparse and heterogeneous literature on these patients, outcomes appear variable but generally worse than reported in the literature for non-radiotherapy related disease. With careful patient selection and treatment, aggressive treatment for such radiotherapy-related cases is feasible and is reasonable option given the limited evidence available.
